



EXHIBIT A

All provisions below will take effect within 90 days of court approval of final settlement, and remain in place for four (4) years from that date.

A. FORMALIZATION OF DISCLOSURE, PRODUCT DEVELOPMENT AND PRODUCT REVIEW COMMITTEES

1. The Company will continue to maintain its management-level Disclosure Committee (formed in April 2021), its Product Development Committee (formed in May 2025), and its Product Review Committee (formed in May 2025) and will formalize the protocols for each such committee by the adoption of a charter or specific duties and responsibilities. Each committee will hold periodic meetings, but in no event less than on a quarterly basis, maintain regular minutes and/or notes of its meetings, and have action items, as needed.
2. The responsibilities of the Disclosure Committee shall include the following:
 - a. The Disclosure Committee shall help ensure the accuracy and completeness of the Company's periodic disclosure filings with the Securities and Exchange Commission ("SEC") on Forms 10-K and 10-Q;
 - b. On a periodic basis, but in no event less than on a quarterly basis, the Disclosure Committee shall also evaluate and, if appropriate, suggest whether any improvements should be made to the Company's controls and procedures concerning public disclosure of information material to investors in Company securities;
 - c. The Disclosure Committee membership shall include the Company's Chief Financial Officer; General Counsel (or another senior member of the legal department with responsibility for disclosure matters who reports to the General Counsel); and such other officers or employees of the Company deemed appropriate, taking into account, among other things, such person's expertise and responsibility for, and involvement in, the business and operations of the Company and the collection, processing and disclosure of information in the Company's publicly filed reports;
 - d. In advance of any meeting of the Disclosure Committee, members of the committee are expected to review any draft disclosure(s) and provide appropriate updates;
 - e. On a quarterly basis, a representative of the Disclosure Committee shall report to the CEO and the Audit Committee, as appropriate, regarding any material deficiencies identified by the Disclosure Committee;

- f. The Disclosure Committee shall keep the Audit Committee apprised of its activities, as needed and appropriate; and
 - g. The Disclosure Committee will also provide the Audit Committee any information requested by the Audit Committee or the Board and will have access to the Audit Committee as may be necessary or appropriate to advance the purposes of the Disclosure Committee.
 - 3. The responsibilities of the Product Development Committee shall include the following:
 - a. The Product Development Committee shall meet with the relevant engineering teams at least once quarterly;
 - b. Ensure proper compliance with an established protocol or internal control mechanism for testing all proposed product designs and/or proposed changes to existing designs;
 - c. In the event of a material problem with any of the Company's technological development capabilities and development efforts:
 - i. investigate the facts and circumstances leading to the problem, including, at a minimum, what happened, whether the issue was a result of a technical problem or personal misconduct, and whether the Company or a third party was responsible for the problem; and
 - ii. provide a report to the Company's COO which details the investigative process employed by the Product Development Committee, including the individuals interviewed, a summary of the facts and circumstances, whether any misconduct or violation of Company policy was uncovered, whether the matter was an isolated incident or had, has, or may have a Company-wide impact, and the remedial measures implemented or to be implemented;
 - 4. The COO shall meet with the Disclosure Committee and the Product Development Committee on a periodic basis, but in no event less than on a quarterly basis, and shall promptly report any material risks identified by either committee to the Board.

B. QUALITY CONTROL OMBUDSMAN

- 1. Beauty Health will designate an existing employee (e.g., Vice President – Quality Assurance) to also act as a Quality Ombudsman ("QO"), to serve as a liaison between personnel working in quality control and product testing, senior management and the Board of Directors ("Board"). The QO will be consulted by executive leadership throughout the development process

and before any product launches, as well as monitor customer complaints and suggest corrective action regarding any material issues promptly.

- a. The QO shall report to the Board on an annual basis or more frequently if necessary as to the methodologies undertaken by the Company to ensure that all new products are of acceptable quality.
- b. Reasonably prior to any new product introduction, the QO shall certify to management that the new product has undergone Alpha and Beta testing consistent with industry standards, and that these tests indicate that the product is market ready, and free of any material defects.
- c. Each quarter after a new product introduction, the QO shall obtain a tabulation of product returns, and inform management and the Audit Committee if such returns exceed expected levels.
- d. The Company shall not dismiss or replace the QO without the approval of the Chair of the Audit Committee should have the power to dismiss or replace the QO.
- e. The QO shall meet with the Product Development and Product Review Committees semi-annually or more frequently as needed.
- f. The QO's compensation shall not be materially reduced without the approval of the Chair of the Compensation Committee.

C. ENHANCED INVENTORY CONTROL

1. On a quarterly basis, the COO or its designee shall create a report detailing the Company's current inventory, including sales and returns, with a description of the reason as to the returns; and these inventory reports shall be provided to the Board.

D. AUDIT COMMITTEE

1. The Charter of the Audit Committee shall be amended within 90 days of final settlement approval to provide that the Audit Committee is responsible to oversee any financial projections to be provided to the public, and ensure that the underlying basis of such projections is reasonable under the circumstances, taking into account any risk that is identified.

E. AMENDED CLAWBACK POLICY

1. Within 90 days of final settlement approval, Beauty Health shall adopt a Second Amended and Restated Clawback Policy which will apply to officers and non-executive officers not otherwise subject to the recoupment policy.

2. The Second Amended and Restated Clawback Policy will provide that, in the event of: (1) credible accusations of fraud or reckless misrepresentation or omission; or (2) a violation of the Company's Corporate Governance Guidelines, the Board shall review the incentive-based compensation, discretionary cash and/or time based equity awards that were received by any person subject to the Policy deemed wholly or partially responsible.

3. In the event the Board determines compensation was received by such recipient that would not have been awarded had the misconduct been known, the Board may recover all such compensation received by that individual.